Total Payments
$459,942
2024 Payments
$5,276
Companies
40
Transactions
928
Medicare Patients
1,321
Medicare Billing
$779,828
Payment Breakdown by Category
Other$325,009 (70.7%)
Travel$65,211 (14.2%)
Research$38,933 (8.5%)
Food & Beverage$19,725 (4.3%)
Consulting$10,966 (2.4%)
Education$98.17 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $220,159 | 95 | 47.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $93,600 | 24 | 20.4% |
| Travel and Lodging | $65,211 | 220 | 14.2% |
| Unspecified | $38,933 | 26 | 8.5% |
| Food and Beverage | $19,725 | 549 | 4.3% |
| Consulting Fee | $10,966 | 7 | 2.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,900 | 2 | 1.5% |
| Honoraria | $4,350 | 2 | 0.9% |
| Education | $98.17 | 3 | 0.0% |
Payments by Type
General
$421,009
902 transactions
Research
$38,933
26 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $101,699 | 161 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $100,279 | 130 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $75,328 | 70 | $0 (2017) |
| Shire North American Group Inc | $50,761 | 119 | $0 (2019) |
| QOL Medical, LLC | $46,131 | 114 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $27,982 | 46 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $20,736 | 19 | $0 (2023) |
| ABBVIE INC. | $8,852 | 66 | $0 (2024) |
| Prometheus Laboratories Inc. | $7,759 | 16 | $0 (2017) |
| Eli Lilly and Company | $6,126 | 9 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,276 | 82 | GENZYME CORPORATION ($1,767) |
| 2023 | $11,754 | 56 | QOL Medical, LLC ($6,362) |
| 2022 | $19,726 | 66 | E.R. Squibb & Sons, L.L.C. ($10,556) |
| 2021 | $42,302 | 80 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($14,428) |
| 2020 | $21,167 | 48 | QOL Medical, LLC ($15,939) |
| 2019 | $26,857 | 83 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($14,687) |
| 2018 | $87,255 | 122 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($61,181) |
| 2017 | $245,606 | 391 | Allergan Inc. ($86,193) |
All Payment Transactions
928 individual payment records from CMS Open Payments — Page 1 of 38
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: Gastroenterology | ||||||
| 12/21/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $12.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $123.30 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: Immunology | ||||||
| 12/10/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $10.79 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/27/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/20/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $27.45 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/14/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $57.89 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: IMMUNOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: Gastroenterology | ||||||
| 10/30/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $22.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Gastroenterology | ||||||
| 10/23/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $51.27 | General |
| 10/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/18/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $7.75 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/17/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $43.11 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/17/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/09/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $26.94 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/18/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.64 | General |
| Category: Neuroscience | ||||||
| 09/10/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: IMMUNOLOGY | ||||||
| 09/03/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $11.23 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/28/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $118.45 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/28/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, MULTIREGIONAL, ONE YEAR STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ORAL RIFAXIMIN DELAYED RELEASE TABLETS FOR INDUCTION OF CLINICAL REMISSION WITH ENDOSCOPIC RESPONSE AT 16 WEEKS FOLLOWED BY CLINICAL AND ENDOSCOPIC REMISSION AT 52 WEEKS IN SUBJECTS WITH ACTIVE MODERATE CROHN'S DISEASE | Valeant Pharmaceuticals North America LLC | $32,947 | 18 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $3,291 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $1,384 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $1,178 | 2 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $132.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 261 | 4,834 | $1.1M | $146,251 |
| 2022 | 9 | 317 | 3,859 | $951,447 | $136,043 |
| 2021 | 11 | 348 | 5,357 | $1.3M | $214,436 |
| 2020 | 12 | 395 | 6,134 | $1.4M | $283,098 |
Total Patients
1,321
Total Services
20,184
Medicare Billing
$779,828
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 19 | 4,300 | $860,000 | $112,651 | 13.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 20 | 114 | $64,655 | $11,543 | 17.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 77 | 172 | $67,940 | $10,747 | 15.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 82 | 165 | $38,775 | $6,033 | 15.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 26 | 28 | $47,498 | $2,291 | 4.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 16 | $7,138 | $1,536 | 21.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $4,223 | $855.90 | 20.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 13 | 27 | $2,025 | $593.21 | 29.3% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 13 | 3,190 | $638,000 | $89,646 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 93 | 303 | $119,550 | $20,137 | 16.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 80 | $45,372 | $8,478 | 18.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 83 | 156 | $36,660 | $5,619 | 15.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 45 | $20,076 | $4,497 | 22.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $10,127 | $2,240 | 22.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 28 | 28 | $47,498 | $1,914 | 4.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 13 | 13 | $25,070 | $1,911 | 7.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 25 | 25 | $9,094 | $1,601 | 17.6% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2021 | 20 | 4,530 | $898,000 | $150,393 | 16.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 89 | 374 | $139,401 | $26,340 | 18.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 58 | 126 | $55,182 | $12,718 | 23.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 22 | 109 | $61,819 | $12,576 | 20.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 64 | 105 | $21,242 | $4,532 | 21.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 24 | 28 | $47,498 | $2,038 | 4.3% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 11 | 11 | $21,213 | $1,712 | 8.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $6,396 | $1,581 | 24.7% |
About Dr. Chandar Singaram, MD
Dr. Chandar Singaram, MD is a Gastroenterology healthcare provider based in Sioux Falls, South Dakota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235183807.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chandar Singaram, MD has received a total of $459,942 in payments from pharmaceutical and medical device companies, with $5,276 received in 2024. These payments were reported across 928 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($220,159).
As a Medicare-enrolled provider, Singaram has provided services to 1,321 Medicare beneficiaries, totaling 20,184 services with total Medicare billing of $779,828. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Sioux Falls, SD
- Active Since 05/19/2006
- Last Updated 03/15/2023
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1235183807
Products in Payments
- LINZESS (Drug) $105,793
- XIFAXAN (Drug) $53,121
- GATTEX (Drug) $50,862
- Sucraid (Drug) $35,519
- RIFAXIMIN (Drug) $32,947
- APRISO (Drug) $32,049
- Trulance (Drug) $27,982
- TRULANCE (Drug) $26,477
- ZEPOSIA (Drug) $23,902
- UCERIS (Drug) $12,349
- RELISTOR (Drug) $11,391
- SUCRAID (Drug) $10,611
- VIBERZI (Drug) $3,286
- DUPIXENT (Biological) $2,011
- Zelnorm (Drug) $2,000
- SOLESTA (Device) $942.61
- ZENPEP (Drug) $570.69
- Epclusa (Drug) $530.61
- VOQUEZNA (Drug) $524.26
- IBSRELA (Drug) $422.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Sioux Falls
Cristina Hill Jensen, M.d, M.D
Gastroenterology — Payments: $22,564
Gastroenterology $22,564
Kozhikode Veetil Menon, M.d., M.b., B.s, M.D., M.B., B.S
Gastroenterology — Payments: $6,050
Gastroenterology $6,050
Jeffrey Murray, M.d, M.D
Gastroenterology — Payments: $3,530
Gastroenterology $3,530
Jorge Gilbert, M.d, M.D
Gastroenterology — Payments: $2,159
Gastroenterology $2,159
Dr. Robert Meyer, M.d, M.D
Gastroenterology — Payments: $1,834
Gastroenterology $1,834
Dr. Ahmed Kurdi, M.d, M.D
Gastroenterology — Payments: $990.54
Gastroenterology $990.54